Type:10 Tablets
Generic Name:Sitagliptin
Manufacturer:The ACME Laboratories Ltd.
Price:৳280.40
Type 2 diabetes mellitus
May be taken with or without food.
Oral Type 2 diabetes mellitus Adult: 100 mg once daily. Hepatic impairment Mild to moderate impairment: Dose adjustment not necessary Severe impairment: Not studied
Safety and efficacy not established
Renal impairment CrCl >50 mL/min: Dose adjustment not necessary CrCl 30-50 mL/min: 50 mg PO qDay CrCl <30 mL/min: 25 mg PO qDay ESRD: 25 mg PO qDay regardless of hemodialysis
Hypersensitivity reactions such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome can occur. Type 1 diabetes. Diabetic ketoacidosis.
Sitagliptin inhibits dipeptidyl peptidase IV (DPP-IV), resulting in prolonged active incretin levels. Incretin hormones increases insulin synthesis and release from pancreatic beta-cells and reduces glucagon secretion from pancreatic beta-cells. Reduced glucagon secretion leads to decreased hepatic glucose production.
Patient w/ type 1 diabetes, history of angioedema. Not intended for the treatment of diabetic ketoacidosis. Moderate and severe renal impairment. Pregnancy and lactation. Monitoring Parameters Monitor glycosylated Hb (HbA1c), serum glucose. Assess renal function prior to initiation of therapy and periodically thereafter. Lactation: Not known whether excreted in breast milk: use caution
1-10% Nasopharyngitis (5%),Diarrhea (4%),Headache (3.6%),Constipation (3%),Peripheral edema (2%),Nausea (2%),Pharyngitis (1%),Osteoarthritis (1%),URI (1%) <1% Hypersensitivity reactions such as anaphylaxis, angioedema, rash, urticaria, cutaneous vasculitis, and exfoliative skin conditions (including Stevens-Johnson syndrome) Hepatic enzyme elevations,Acute pancreatitis, including fatal and nonfatal hemorrhagic and necrotizing pancreatitis.Constipation.Vomiting.Worsening renal function, including acute renal failure (sometimes requiring dialysis),Severe and disabling arthralgia,Myalgia,Pain in extremity,Back pain
Increased risk of hypoglycaemia when used in combination w/ sulfonylureas or insulin.
